Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2015-11-10 Declaration of Voting R…
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document provides specific, periodic information regarding the total number of shares and voting rights ('nombre total de droits de vote et d'actions') as required by French commercial code (Article L. 233-8 II) and AMF regulations (Article 223-16). This type of filing, detailing share capital structure and voting power, is typically a mandatory regulatory disclosure. It is not an Annual Report (10-K), Earnings Release (ER), or a general announcement about a report (RPA). While it relates to capital structure, it is a specific regulatory disclosure about voting rights rather than a general financing activity (CAP) or a major shareholding change notification (MRQ). Given the specific nature of reporting voting rights based on AMF rules, and lacking a perfect fit among the primary options, it most closely aligns with a specific regulatory disclosure. However, since the content is purely about the structure of voting rights and share count, and not a change in ownership threshold (MRQ) or a general capital change (SHA), it falls into the category of specific regulatory reporting. In many databases, these periodic voting rights disclosures are often categorized under general regulatory filings or specific capital structure updates. Since it is a formal, periodic disclosure mandated by regulators, and it doesn't fit the definitions for DIV, SHA, or MRQ precisely (as it's a statement of the current total, not a transaction or threshold breach), the closest fit among the provided options that covers specific regulatory disclosures not covered elsewhere is RNS (Regulatory Filings/Miscellaneous). If a specific 'Voting Rights Disclosure' code existed, that would be preferred. Given the options, RNS is the most appropriate fallback for a specific, mandated regulatory disclosure that doesn't match the other specific codes.
2015-11-10 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is a press release dated October 15, 2015, announcing that the CEO of ABIVAX will be presenting at two upcoming industry conferences: BIO Europe 2015 and Deutsches Eigenkapitalforum. This type of announcement, detailing management participation in investor-facing events (like conferences where presentations are given), is best classified as an Investor Presentation (IP) related announcement or, more broadly, a general corporate update. Since the document itself is an announcement about future presentations rather than the presentation slides or a transcript of a call, and it focuses on corporate strategy and development programs being shared with investors, it aligns closely with the intent of an Investor Presentation (IP) or a general corporate/investor relations communication. Given the options, and since it is not a formal regulatory filing, earnings release, or a report itself, but rather an announcement about management sharing information with investors, 'Investor Presentation (IP)' is the most fitting category, as these announcements often precede or accompany such events. However, if the document were strictly about the *timing* of a report release, it would be RPA. Since it's about management presenting company strategy/pipeline at investor conferences, IP is the best fit among the specific choices, although RNS (Regulatory Filings) is a possibility if IP is deemed too specific for an announcement *about* presentations. Given the content focuses heavily on the development program and strategy being presented, IP is chosen over the generic RNS.
2015-10-15 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a short press release from ABIVAX dated October 15, 2015. The content explicitly announces the participation of the CEO in two upcoming investor/industry conferences (BIO Europe 2015 and Deutsches Eigenkapitalforum) and provides the presentation times. This type of announcement, detailing future events where company information will be shared, is best classified as an Investor Presentation (IP) announcement or, more generally, a communication aimed at investors regarding future engagement. Since it is not the presentation itself, but an announcement about participation in investor events, and it is short, it fits the pattern of an announcement. However, given the specific options, this is a direct announcement about investor engagement and presentation schedules, which is a common precursor to an Investor Presentation (IP) or a general update. Since there is no specific code for 'Conference Participation Announcement', and it is not a formal regulatory filing, earnings release, or dividend notice, it is a communication directed at investors about future strategy/pipeline updates. The closest fit among the options that covers general investor communications about strategy/pipeline updates presented at events is 'Investor Presentation' (IP), although it is technically an announcement *about* presentations. Given the context of financial reporting, this is a standard investor relations communication.
2015-10-15 French
Communiqués en période d’offre / Autres communiqués
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document provides specific data regarding the total number of shares and voting rights ('nombre total de droits de vote et d'actions') as of a specific date (30/09/2015). It explicitly references French regulatory articles (Article L. 233-8 II du code de commerce and Article 223-16 du règlement général de l'Autorité des marchés financiers - AMF). This structure, detailing share capital and voting power, is characteristic of regulatory disclosures concerning share structure changes or periodic updates on voting rights, which often fall under general regulatory announcements or specific capital structure notifications. Since it is a direct disclosure of share/voting data rather than a general announcement of a report (RPA) or a major shareholding change by an external party (MRQ), and it deals directly with the capital structure's voting components, it aligns best with a general regulatory filing or a specific capital/share structure update. Given the options, it is a direct regulatory disclosure about the company's share structure, which is often reported via RNS or related to capital changes. However, the content is a direct, periodic disclosure of voting rights, which is a specific regulatory requirement. It is not a dividend announcement (DIV), a major shareholder notification (MRQ), or a general share issue (SHA). It is a direct regulatory filing about the capital structure's voting rights. Since there isn't a perfect fit for 'Voting Rights Disclosure', the closest specific category dealing with share structure is SHA (Share Issue/Capital Change), but this is a periodic disclosure of existing rights, not an issue. Therefore, the most appropriate fallback for a specific, non-standard regulatory disclosure is RNS (Regulatory Filings).
2015-10-13 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a short press release dated October 1, 2015, announcing ABIVAX's participation in the 'Large & Midcap Event' on October 7-8, 2015, where management will present the company's strategy and news. It is not a full financial report (like 10-K or IR), nor is it a formal regulatory filing like a Director's Dealing or Major Shareholding notification. It is an announcement about an upcoming investor event where presentations will occur. This fits best under Investor Presentation (IP) if it were the presentation itself, but since it is an announcement *about* attending an event to present, and given the short length and nature (announcement of activity), it most closely aligns with a general announcement or a precursor to an investor presentation. However, none of the categories perfectly capture a simple event attendance announcement. Given the options, it is a general corporate update. Since it is not a formal regulatory filing (RNS) and doesn't fit the specific financial/governance categories, and it is an announcement of management interaction with investors, it is closest to a general corporate update. If the presentation materials were attached, it would be IP. As a short announcement about management meeting investors, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback, although it could also be argued as a precursor to an Investor Presentation (IP). Given the content focuses on management presenting strategy at an event, I will lean towards RNS as the general announcement category for non-standard corporate news, as it is not a formal release of results (ER) or a specific transaction report.
2015-10-01 French
Document availability communications / Half yearly financial report
Report Publication Announcement Classification · 1% confidence The document explicitly announces the 'AVAILABILITY OF THE HALF-YEAR FINANCIAL REPORT AS OF 30 JUNE 2015' and states that this report 'is now available and has been filed with the Autorité des Marchés Financier (AMF)'. The document itself is short (3175 characters) and serves primarily to inform the public that the actual report document is ready and accessible elsewhere ('The report is available on ABIVAX's website'). According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating a report has been published points to a Report Publication Announcement (RPA). Although the content relates to an Interim/Quarterly Report (IR), the document's function here is the announcement of its publication.
2015-09-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.